NY-REVBITS
22.5.2023 15:16:25 CEST | Business Wire | Press release
RevBits announces that it has successfully completed the architectural development of its privileged access management solution for deployment in a true air gapped environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005003/en/
RevBits Privileged Access Management (RB/PAM) is an advanced access management solution that includes seven modules and extensive session logging that captures keystrokes and video. These unique access control capabilities and multi-module offerings reduce vendor relationship management efforts and increase access management safeguards.
RevBits PAM has two U.S. patents - a browser-based zero-knowledge encryption and authentication authority that extends to various hardware security solutions.
RevBits PAM modules:
Privileged Access Management - regulates access to critical resources, captures keystrokes, and video records all privileged sessions.
Privileged Session Management - provides keystroke and query logging for all sessions through the solution's Jump Server.
Password Management - extends authentication security with hardware security modules, USB tokens, smart cards, near-field communications, and RFID.
Service Account Management - scans and onboards service accounts and scheduled tasks for IIS web applications.
Key Management - allows users to easily generate and store encryption keys.
Certificate Management - reports all expired or soon-to-expire certificates and vulnerable implementations of SSL.
CI/CD Integration - the CI/CD module plugs into your current platform and unlocks the capabilities of secure secret management across the CI/CD lifecycle, allowing for easy management of CI/CD users, credentials, and assets.
Defining Air Gap:
Techopedia: "An air gap is a security measure that isolates a digital device component or private local area network (LAN) from other devices and networks, including the public internet. An air gap is also known as an air wall, and the strategy of using air gaps to protect critical data is also known as security by isolation.
Air gaps are used to protect critical computer systems and the data they store from malware, keyloggers, ransomware, and other types of unauthorized access. This strategy seeks to ensure the total isolation of a given system electromagnetically, electronically, and physically."
RevBits Privileged Access Management – our Air Gap capability:
Inside the air gap environment sit servers and assets critical to the organization. As important as it is to protect against malware and ransomware attacks, it is equally important to protect the data on those servers from malicious acts and theft in an air gap environment.
RevBits Privileged Access Management is fully featured in an air gapped environment allowing for complete server security and data protection. Server access is monitored through extensive session monitoring, including video recording and keystroke logging.
About RevBits
Established in 2018, RevBits is a comprehensive cybersecurity company dedicated to providing customers with superior protection and service. RevBits delivers protection against the most sophisticated cyber threats companies face by offering multiple advanced security capabilities that can be administered through a unified security platform. RevBits is headquartered in Mineola, NY, with offices in Princeton, NJ; Boston, MA; London, England; and Antwerp, Belgium. For more information please visit RevBits.
RevBit's complete solution suite offerings are RevBits Endpoint Security, RevBits Email Security, RevBits Privileged Access Management, RevBits Zero Trust Network, and RevBits Deception Technology. For customers running more than one RevBits solution, the administration is managed through RevBits Cyber Intelligence Platform, a unified, single-pane environment that curates, correlates, and alerts to threats while delivering intelligence for a quick administrative response. RevBits Cyber Intelligence Platform integrates with all common SIEMs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
